Tursun Alkam

Tursun Alkam Email and Phone Number

Neuroscience | Applied AI | In Vivo Research @ Memory Transplant, Corp.
Tursun Alkam's Location
Los Angeles Metropolitan Area, United States
About Tursun Alkam

A seasoned Neuroscientist with over 20 years of expertise in neuropsychopharmacology, neurodegenerative disease research, CNS drug discovery, and strategic content development. Proficient in leading cutting-edge laboratories with a focus on advanced histological and imaging techniques, and adept at developing and executing both preclinical and translational research projects. Recognized for groundbreaking work in anti-inflammatory strategies (anti-TNF-a and thalidomide) for Alzheimer’s disease, with a robust publication record and a commitment to fostering innovative therapeutic solutions. Demonstrates strong leadership and collaboration skills, with extensive experience in guiding cross-functional teams and driving projects from discovery to clinical application.CORE COMPETENCIES• Leadership & Team Management: Proven ability to lead diverse research teams, manage complex laboratories, and oversee large-scale projects to achieve targeted outcomes.• Advanced Histology & Imaging: Expertise in designing and optimizing histological assays, coupled with the implementation of cutting-edge imaging methods for both in vivo and in vitro samples.• Drug Development & Translational Research: Comprehensive experience in identifying biomarkers, advancing CNS therapeutic candidates, and bridging the gap between preclinical research and clinical trials (Thalidomide and Rosmarinic Acid).• Specialization in Neurodegenerative Diseases: Deep understanding of neurodegenerative mechanisms, with a particular focus on Alzheimer’s disease research and therapeutic innovation.• Scientific Communication: Published over 25 peer-reviewed articles and book chapters, with a talent for translating complex scientific concepts to various audiences.• Strategic Collaborations & Partnerships: Skilled in establishing and maintaining strategic partnerships with pharmaceutical companies, academic institutions, and government agencies.

Tursun Alkam's Current Company Details
Memory Transplant, Corp.

Memory Transplant, Corp.

View
Neuroscience | Applied AI | In Vivo Research
Tursun Alkam Work Experience Details
  • Memory Transplant, Corp.
    Chief Scientist
    Memory Transplant, Corp. Jan 2020 - Present
    Los Angeles County, California, United States
    As Chief Scientist at BrainAID AI, I lead the development of innovative AI technologies that address the challenges of Alzheimer’s disease and mental health, particularly supporting caregivers of Alzheimer’s patients. My work combines cutting-edge AI research with a compassionate approach to healthcare solutions.Key Achievements:Pioneered AI for Alzheimer’s Care: Led the development of advanced AI models specifically designed to assist in early detection of Alzheimer’s, improve patient care, and provide personalized support to caregivers, enhancing both patient outcomes and caregiver well-being.Aligned AI Innovation with Healthcare Needs: Strategically aligned our AI research with the pressing needs of Alzheimer’s patients and their caregivers, driving the development of tools that monitor cognitive changes and provide mental health support to families impacted by the disease.Advanced AI-Driven Mental Health Solutions: Developed and deployed AI tools that track and enhance mental health, including predictive models to reduce caregiver burnout, emotional strain, and stress-related health issues.Fostered Collaborative Research in Alzheimer’s: Built partnerships with healthcare providers, research institutions, and Alzheimer’s associations to co-develop solutions that blend clinical insights with AI capabilities, contributing to impactful real-world applications.Promoted Ethical and Human-Centered AI: Ensured the ethical development of AI models, focusing on protecting patient data, minimizing algorithmic bias, and maintaining user privacy, particularly within sensitive healthcare environments.Public Engagement and Advocacy: Represented BrainAID AI at healthcare and AI industry events, advocating for the importance of mental health and Alzheimer’s care, and sharing our vision of integrating AI with compassionate caregiving.
    View
  • Western University Of Health Sciences
    Research Scientist
    Western University Of Health Sciences Mar 2013 - Jan 2020
    Pomona, California
    • Supported the acquisition of a $500K grant from DoD by supervising a graduate student in preliminary data collection and assisting in writing the behavioral investigation protocol. Successfully managed and accomplished the grant objectives in a timely manner by training a team of graduate students.• Trained and supervised over 20+ junior researchers, graduate students, medical research volunteers, and summer research students from five different universities in techniques including:1) Various routes of drug administration, including intraperitoneal (i.p.), subcutaneous (s.c.), intravenous (i.v.), and intrathecal (i.t.) injections; and jugular vein cannulation. 2) Tissue dissection from rodent brain and spinal cord.3) Tissue processing for RNA, DNA, and protein extraction.4) Collect aortic blood samples from mice for serum/plasma analysis and perform perfusion to extract the brain for immunohistochemical analyses .5) Skills in reverse transcription polymerase chain reaction (RT-PCR), ELISA, immunoprecipitation, Western blot, immunohistochemistry, immunofluorescence staining, optical microscopy, fluorescent microscopy, and confocal microscopy.• Published 3 book chapters and 7 peer-reviewed publications related to Schizophrenia and nicotine use.
    View
  • Western University Of Health Sciences
    Molecular Neurobiology Research Fellow
    Western University Of Health Sciences May 2010 - Feb 2013
    Pomona, California
    • Led the hypothesis on calcium signaling in chemotherapy-induced vomiting and established animal models to block calcium signaling, resulting in the amelioration of chemotherapy-induced vomiting. These findings led to the successful procurement of an R01 Grant from NIH and other industry grants, totaling $2.3M. • Authored and co-authored 6 peer-reviewed research papers and 4 conference presentations in the fields of Alzheimer's disease and emetic studies.• Led the clinical laboratory section of an Alzheimer's project, coordinating sample collection, processing, and flow cytometry.• Conducted isolation of white blood cells (CD4+ cells) from (human) blood samples and performed flow cytometry analysis, adhering strictly to ICH-GCP and FDA regulations.• Established an in vitro model of pathological angiogenesis induced by Alzheimer's Aβ using human umbilical vein endothelial cells.
    View
  • Japanese Ministry Of Health, Labour And Welfare
    Research Resident
    Japanese Ministry Of Health, Labour And Welfare Oct 2008 - May 2010
    Established a novel behavioral method to investigate attention in mice. This approach overcame the challenges of examining attention in young mice (P28) without the traditional lengthy training required by the 5CSRT Task, thereby facilitating research in ADHD.Investigated the mechanism of PNE-induced persistent reduction of NE and DA levels in the medial prefrontal cortex (m-PFC) via in-vivo m-PFC micro-dialysis, HPLC, and IHC.
  • Nagoya University
    Researcher Of Center Of Excellence
    Nagoya University 2005 - 2008
    Nagoya, Japan
    • Applied ICV injections to directly deliver peptides into the brain's ventricular system, bypassing the blood-brain barrier, thereby providing pure insights into molecular brain functions and dysfunctions.1) Administered a range of peptides for study, including: Abeta 1-40, Abeta 1-42, Abeta 42-1, Abeta 25-35, Abeta 35-25, ONOO-, and Leu-Ile dipeptide.2) Employed molecular biology techniques: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Immunohistochemistry (ICH) on frozen sections, and Western Blotting (WB).• Key discoveries: Identified TNF-a as a trigger for Abeta neurotoxicity and determined thalidomide as a preventive measure. Recognized NFL hyperphosphorylation as an early biomarker of Abeta pathology in Alzheimer's disease. This study led to a clinical trial of Thalidomide on Alzheimer’s disease in the US.
    View
  • Sasakawa Peace Foundation
    Visiting Medical Researcher
    Sasakawa Peace Foundation Apr 2004 - Mar 2005
    Nagoya, Japan

Tursun Alkam Education Details

Frequently Asked Questions about Tursun Alkam

What company does Tursun Alkam work for?

Tursun Alkam works for Memory Transplant, Corp.

What is Tursun Alkam's role at the current company?

Tursun Alkam's current role is Neuroscience | Applied AI | In Vivo Research.

What schools did Tursun Alkam attend?

Tursun Alkam attended Uc Irvine, Nagoya University, Uc Irvine, University Of San Diego.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.